Core Viewpoint - The company, Brainstorm Aurora-B (06681.HK), has announced its participation in a significant national science and technology project focused on the prevention and treatment of major diseases, highlighting its leadership in digital diagnosis for cognitive disorders [1] Group 1: Project Involvement - The company's wholly-owned subsidiary, Beijing Zhijingspirit Technology Co., Ltd., is a key collaborator in the national science and technology major project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The specific project under this initiative is named "Establishment of Key Technologies for Digital Diagnosis Related to Intracranial Atherosclerotic Stenosis and Cognitive Disorders Based on Deep Reasoning Large Models" with project number 2025ZD0546200 [1] Group 2: Laboratory Establishment - Zhijingspirit Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has successfully applied for the establishment of the "Beijing Key Laboratory for Digital Medical Treatment of Cognitive Disorders," which has recently been approved [1] - The approval of the key laboratory further emphasizes the company's technological leadership in the field of digital diagnosis for cognitive disorders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 本次啟動的國家科技重大專項，聚焦ICAS相關認知障礙的診療難題，依託多 學科交叉優勢開展系統性研究，核心方向包括建立ICAS相關認知障礙的評估 技術體系及深度推理預測大模型，以提供疾病早期篩查、風險預判和預防、 干預的診療工具，並建立ICAS相關認知障礙全場景閉環管理體系。 本項目的實施旨在建立國際領先的ICAS相關認知障礙診療技術體系，構建符 合中國國情的疾病管理模式，有效預防與延緩疾病進展，助力「健康中國」戰 略。本項目由宣武醫院牽頭，聯合中國醫學科學院北京協和醫院、中國科學 院心理研究所、吉林大學、北京師範大學及智精靈科技等單位共同攻關。研 究團隊匯集了神經病學、認知神經科學、心理學與人工智能等領域的頂尖專 家，並與國際領先研究團隊保持長 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a significant surge in stock prices, driven by recent developments in regulatory support and technological advancements [1]. Group 1: Stock Performance - Nanjing Panda (00553) increased by 4.16%, reaching HKD 4.51 [1] - MicroPort NeuroTech (02172) rose by 4.24%, trading at HKD 10.83 [1] - BrainCo (06681) saw a 2.58% increase, priced at HKD 5.96 [1] Group 2: Regulatory Developments - The National Medical Products Administration held a meeting on December 18 to advance BCI medical device initiatives [1] - The meeting emphasized the strategic importance of BCI in future industry development and the need for safety and effectiveness as primary considerations [1] - It called for innovative regulatory methods, the establishment of standard systems, and enhanced technical guidance [1] Group 3: Industry Outlook - According to Guotai Junan, the BCI industry is poised for significant growth due to technological breakthroughs, policy support, and capital investment [1] - There is an anticipated release of demand in downstream markets such as healthcare and consumer goods, indicating a promising market outlook [1]

Core Viewpoint - The Hong Kong stock market is experiencing a surge in brain-computer interface concept stocks, indicating growing investor interest in this sector [1] Group 1: Stock Performance - Nanjing Panda (00553.HK) increased by 4.16%, reaching HKD 4.51 [1] - Weikang Brain Science (02172.HK) rose by 4.24%, trading at HKD 10.83 [1] - Brain Motion Aurora-B (06681.HK) saw a gain of 2.58%, priced at HKD 5.96 [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a significant surge in stock prices, driven by government support and technological advancements, indicating a promising market outlook for the industry [1] Group 1: Stock Performance - Nanjing Panda (600775) shares increased by 4.16%, reaching HKD 4.51 [1] - Microwin Brain Science (02172) shares rose by 4.24%, reaching HKD 10.83 [1] - Brain Motion Aurora-B (06681) shares grew by 2.58%, reaching HKD 5.96 [1] Group 2: Regulatory Developments - The National Medical Products Administration held a meeting on December 18 to advance BCI medical device initiatives [1] - The meeting emphasized the strategic importance of BCI in future industry development and the need for safety and effectiveness as primary considerations [1] - It called for enhanced cross-departmental collaboration to address key technical challenges and improve the industry supply chain [1] Group 3: Market Outlook - According to Guotai Junan, the BCI industry is expected to benefit from technological breakthroughs, policy support, and capital investment [1] - There is an anticipated release of demand in downstream markets such as healthcare and consumer goods, indicating a positive market outlook [1]

智通财经APP获悉，脑机接口概念股午前拉升，截至发稿，南京熊猫(00553)涨4.16%，报4.51港元；微 创脑科学(02172)涨4.24%，报10.83港元；脑动极光-B(06681)涨2.58%，报5.96港元。 国泰海通指出，伴随技术创新突破、政策支持引导、资本投入等多重因素驱动，脑机接口行业有望迎来 重要发展机遇，有望在医疗健康、生活消费等下游市场迎来需求释放，市场前景可期。 消息面上，国家药监局12月18日在北京召开脑机接口医疗器械工作推进会。会议要求，要深入贯彻落实 党的二十届四中全会精神，深刻领会脑机接口作为前瞻布局未来产业的重要战略意义；要坚持安全有效 为首要前提，创新审评监管方法，构建标准体系，加强技术指导服务；要加强跨部门合作，联手产学研 医各方，合力解决关键技术问题，完善产业链供应链；要落实企业主体责任，以问题为导向，提升产品 可靠性和整体竞争力，积极推动脑机接口器械更快更好服务临床、惠及患者。 ...

智通财经获悉，脑机概念股集体高开，截至发稿，脑洞极光(06681)涨10.35%，报6.29港元；南京熊猫电 子股份(00553)涨1.63%，报4.36港元。 中信建投认为，脑机接口产业链上中游的技术进步带来下游应用端不断突破，近年来国内外在运动恢 复、语言沟通、听力重建等医疗领域的研究不断出现里程碑式成果。国家层面和各地区推出多项政策利 好行业加速发展，近期国家医保局发文为脑机接口新技术价格单独立项，其进入临床应用的服务收费路 径已经铺好。在技术革新和政策红利催化下，国内脑机接口公司有望逐步实现商业化应用。 本文源自：智通财经网 消息面上，据证券时报报道，中国科学院脑科学与智能技术卓越创新中心赵郑拓、李雪研究团队今年已 联合相关医院和企业，完成三例侵入式脑机接口临床试验，在生活场景应用方面实现突破。其中，在第 二例临床试验中，研究团队采用高通量无线侵入式脑机接口系统，使一位高位截瘫患者能够通过脑电信 号稳定操控智能轮椅与机器狗，在真实生活场景中实现自主移动与物品取用。 ...

每经AI快讯，港股脑机概念股集体高开。截至发稿，脑洞极光(06681.HK)涨10.35%，报6.29港元；南京 熊猫电子股份(00553.HK)涨1.63%，报4.36港元。 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant advancements, with recent clinical trials demonstrating practical applications that could lead to commercial opportunities in the healthcare industry [1] Industry Developments - The brain-computer concept stocks opened high, with notable increases such as Brainhole Aurora (06681) rising by 10.35% to HKD 6.29 and Nanjing Panda Electronics (600775) increasing by 1.63% to HKD 4.36 [1] - A research team from the Chinese Academy of Sciences has completed three invasive BCI clinical trials in collaboration with hospitals and enterprises, achieving breakthroughs in real-life applications [1] Clinical Trial Highlights - In the second clinical trial, a high-level paraplegic patient was able to control a smart wheelchair and robotic dog using brain signals, demonstrating the potential for autonomous movement and object retrieval in real-life scenarios [1] Market Outlook - CITIC Securities believes that technological advancements in the midstream of the BCI industry are leading to breakthroughs in downstream applications, with significant milestones in medical fields such as motor recovery, communication, and hearing restoration [1] - National and regional policies are being introduced to accelerate industry development, including a recent announcement from the National Healthcare Security Administration to establish a separate pricing item for new BCI technologies, paving the way for clinical application service charges [1] - With technological innovations and policy support, domestic BCI companies are expected to gradually achieve commercialization [1]

Core Viewpoint - The brain-machine interface (BMI) sector is experiencing significant advancements, with recent clinical trials demonstrating practical applications that could lead to commercial opportunities in the healthcare industry [1] Industry Developments - The brain-machine concept stocks opened high, with notable increases in share prices: Brainhole Aurora (06681) up 10.35% to HKD 6.29 and Nanjing Panda Electronics (00553) up 1.63% to HKD 4.36 [1] - A research team from the Chinese Academy of Sciences has completed three invasive BMI clinical trials, achieving breakthroughs in real-life applications [1] Clinical Trial Achievements - In the second clinical trial, a high-level paraplegic patient was able to control a smart wheelchair and robotic dog using brain signals, demonstrating the potential for independent mobility and object retrieval in real-life scenarios [1] Market Outlook - CITIC Securities believes that technological advancements in the upstream BMI industry are leading to breakthroughs in downstream applications, particularly in rehabilitation, communication, and hearing restoration [1] - The Chinese government and various regions are implementing policies to accelerate the industry's development, including the National Healthcare Security Administration's recent decision to separately list pricing for new BMI technologies [1] - With technological innovations and policy support, domestic BMI companies are expected to gradually achieve commercial applications [1]